Postmenopausal atrophic vaginitis
disease diseaseOn this page
Also known as atrophic vaginitissenile vaginitis
Summary
Postmenopausal atrophic vaginitis (MONDO:0001410) is a disease with 1 GWAS associations across 8 studies and 33 clinical trials. Top therapeutic interventions include estriol, estradiol valerate, and hyaluronic acid. A subtype of vaginitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | postmenopausal atrophic vaginitis |
| Mondo ID | MONDO:0001410 |
| MeSH | D059268 |
| DOID | DOID:11968 |
| ICD-10-CM | N95.2 |
| ICD-11 | 1876048433 |
| SNOMED CT | 52441000 |
| UMLS | C0156409 |
| MedGen | 510282 |
| Is cancer (heuristic) | no |
Also known as: atrophic vaginitis · senile vaginitis
Data availability: 1 GWAS association (8 studies).
Disease family
This is a subtype of vaginitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › vaginal disorder › vaginitis › postmenopausal atrophic vaginitis
Related subtypes (2): vulvovaginitis, infective vaginitis
Genetics & variants
GWAS landscape
1 GWAS associations across 8 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs74973610 | 5e-08 | CEP19P1 - AGAP1 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90478735 | Verma A | 2024 | 2,353 | 28,229 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90080697 | Backman JD | 2021 | 1,317 | 227,817 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90084683 | Backman JD | 2021 | 1,317 | 227,817 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90436531 | Zhou W | 2018 | 1,115 | 377,857 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90651700 | Liu TY | 2025 | 771 | 103,376 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90478734 | Verma A | 2024 | 733 | 15,040 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480916 | Verma A | 2024 | 733 | 15,040 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90482292 | Verma A | 2024 | 254 | 5,533 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs74973610 | 2 | 235178153 | A>G | intron_variant | CEP19P1 - AGAP1 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
4 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Status |
|---|---|
| Estradiol | Approved (phase 4) |
| Estrogens, Conjugated | Approved (phase 4) |
| Ospemifene | Approved (phase 4) |
| Prasterone | Approved (phase 4) |
3 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Estradiol Valerate | Phase 3 |
| Estriol | Phase 3 |
| Oxytocin | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 13 |
| PHASE4 | 6 |
| PHASE3 | 5 |
| PHASE1 | 5 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06808347 | PHASE4 | NOT_YET_RECRUITING | Difference in Serum Estrogen Level Based on Methods of Vaginal Estrogen Application (fingertip Vs Applicator Use) in Post-menopausal Women |
| NCT07346287 | PHASE4 | RECRUITING | ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy |
| NCT02014428 | PHASE4 | COMPLETED | Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis |
| NCT02869165 | PHASE4 | COMPLETED | Vaginal and Urinary Microbiome Trial |
| NCT03996603 | PHASE4 | COMPLETED | Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy |
| NCT04079218 | PHASE4 | COMPLETED | Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial |
| NCT00137371 | PHASE3 | COMPLETED | Study Evaluating Conjugated Estrogen Cream for Atrophic Vaginitis |
| NCT00816556 | PHASE3 | TERMINATED | A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis |
| NCT02195986 | PHASE3 | COMPLETED | A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis |
| NCT02995694 | PHASE3 | COMPLETED | A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis |
| NCT03294538 | PHASE3 | COMPLETED | Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis |
| NCT06176820 | PHASE2/PHASE3 | UNKNOWN | Vaginal Hyaluronic Acid, Arginine and Liposome Gel Versus Vaginal Lubricant in Postmenopausal Women With Genitourinary Syndrome of Menopause |
| NCT02313545 | PHASE1/PHASE2 | COMPLETED | Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV |
| NCT02460302 | PHASE2 | WITHDRAWN | Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy |
| NCT00167921 | PHASE1 | COMPLETED | Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis |
| NCT01370551 | PHASE1 | COMPLETED | Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients |
| NCT02733731 | PHASE1 | UNKNOWN | The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis |
| NCT03898401 | PHASE1 | UNKNOWN | Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis |
| NCT05118685 | PHASE1 | UNKNOWN | Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis |
| NCT02029053 | EARLY_PHASE1 | COMPLETED | Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness |
| NCT04045379 | Not specified | ACTIVE_NOT_RECRUITING | LASER and Radiofrequency and Genitourinary Syndrome of Menopause |
| NCT05953090 | Not specified | RECRUITING | VALOR: Vaginal Atrophy & Long-term Observation of Recovery |
| NCT00984399 | Not specified | COMPLETED | Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen |
| NCT02691936 | Not specified | COMPLETED | Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy |
| NCT03981458 | Not specified | UNKNOWN | Hyaluronate for the Treatment and Prevention of Recurrent Urinary Tract Infection in Women Suffering Atrophic Vaginitis |
| NCT04219605 | Not specified | COMPLETED | Evaluation of a Rapid Microscopic Diagnostic System for Different Vaginitis Conditions |
| NCT04247022 | Not specified | COMPLETED | Evaluation of Gynecological Acceptability of a Health Care Product |
| NCT04327947 | Not specified | COMPLETED | Evaluation of Gynecological Acceptability of 3 Health Care Products |
| NCT04579991 | Not specified | UNKNOWN | Effects of Visnadin, Ethyl Ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women |
| NCT05058313 | Not specified | COMPLETED | Evaluation of the Safety and Performance of the MILTA GYNECO Vaginal Probe in Postmenopausal Women With Vaginal Atrophy |
| NCT05396261 | Not specified | COMPLETED | a Flexible Wound Dressing for the Management of Genital Skin Conditions |
| NCT05432154 | Not specified | COMPLETED | An Innovative Silicone Wound Dressing for the Management of Atrophic Vaginitis |
| NCT06305494 | Not specified | UNKNOWN | Genitourinary Syndrome of Menopause in Thai Gynecologic Cancer Survivors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ESTRIOL | 4 | 4 |
| ESTRADIOL VALERATE | 4 | 1 |
| HYALURONIC ACID | 4 | 1 |
Related Atlas pages
- Drugs: Estriol, Estradiol Valerate, Hyaluronic Acid